Gallium-68 PSMA PET scanning “is a game changer” in prostate cancer

The “game changer” statement above comes from an independent review of the potential value of gallium-86-labeled prostate-specific molecular antigen (68Ga PSMA) PET scanning in the evaluation of selected men with prostate cancer. … READ MORE …

Prediction of potentially lethal forms of prostate cancer

An international, multi-institutional group of researchers appears to have been able to validate a new way to predict risk for aggressive forms of localized prostate cancer that have a high probability for progression to metastatic disease and prostate cancer-specific mortality. … READ MORE …

Are genomic tests for prognostic risk at diagnosis really helpful (yet)?

One of the critical and unanswered questions about the value of genomic/genetic testing in relation to the diagnosis and prognosis of prostate cancer is, “What are the currently available tests actually telling us compared to the clinical data?” … READ MORE …

Minimal residual disease and the management of prostate cancer

The concept of “minimal residual disease” or MRD and how it affects risk for cancer-specific mortality is a subject of growing importance in the management of many cancers. But it is relatively new to the world of prostate cancer. … READ MORE …

Could “single cell genomics” replace Gleason grading in prostate cancer risk evaluation?

According to a study just published in Cancer Research, a completely new technique referred to as “single cell genomics” may be able to improve the accuracy of diagnosis of prostate cancer based on biopsy tissue. … READ MORE …

Understanding genetics, genomics, and their utility in prostate cancer

Our friends at UroToday have just published a perfectly lovely lecture on this topic given by Prof. Lenny Gomella at the recent annual meeting of the Large Urology Group Practice Association (LUGPA). … READ MORE …

The accurate prognosis of recurrence- and metastasis-free survival

A company based on Northern Ireland called Almac Diagnostics has been working on the development of a 70-gene genetic assay (which they refer to as their Prostate Cancer Metastatic Assay) capable of projecting probability of metastasis-free survival in men treated for prostate cancer. … READ MORE …